Stimulation of celiac vagal fibers with simultaneous high-frequency alternating current block of liver fibers decreases glucose variability in a porcine model of type 2 diabetes
SAN CLEMENTE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — Reshaping life sciences™ (Nasdaq: RSLS), the leading physician-led weight loss and metabolic health solutions company, today announced the presentation of data on its proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device in an abstract at the annual meeting of the Obesity Society, during ObesityWeek® conference to be held in San Diego, California, November 1-4, 2022, with continued virtual access through December 31, 2022.
“Despite medications, surgery and diet, type 2 diabetes remains difficult to treat effectively,” said Jonathan Waataja, director of research at ReShape Lifesciences. “Encouragingly, the company’s technology has demonstrated both safety and efficacy in a porcine model of type 2 diabetes, showing that bioelectronic modulation of nerves innervating organs that regulate plasma glucose (PG) , using our proprietary DBSN™ device, may be a new treatment option. for type 2 diabetes.
The reported summary is as follows:
Metabolic effects of dual vagus nerve neuromodulation in a model of type 2 diabetes
Session title: Neuroscience
Authors: Raj Nihalani, MD, Jonathan Waataja, Ph.D., Charles Billington, MD
Autonomic vagus nerve stimulation, or vagotomy treatments, have mixed or undesirable results. Neuromodulation consisting of stimulation of celiac fibers innervating the pancreas with simultaneous reversible electrical blockade of neuronal hepatic fibers innervating the liver is a new therapeutic concept that has been successfully tested in animal models of type 2 diabetes mellitus (T2DM). Previously, the area under the oral glucose tolerance test (OGTT) curve was calculated to quantify glycemic control. However, blood glucose fluctuations during OGTT were not consulted. These fluctuations may be of importance in the treatment of T2DM, as large fluctuations in PG have been shown to increase oxidative stress and lead to comorbidities in T2DM. As part of this study, these fluctuations were investigated during OGTTs in diabetic pigs. Celiac fibers were stimulated at a frequency of 1 Hz with the simultaneous application of a high frequency (5000 Hz) alternating current blockade to the liver fibers. Standard deviation (SD) and percent coefficient of variation (%CV) were used to quantify glycose variability during OGTT in an alloxan-treated porcine model of type 2 diabetes (n = 3 w/ 3 OGTT). DBSN™ was found to significantly decrease SD and %CV compared to placebo.
“The opportunity to present such compelling data on our proprietary DBSN™ device at this industry conference speaks to the commercial potential of the technology to treat type 2 diabetes,” said Paul F. Hickey, President and CEO from the management of ReShape Lifesciences. “Backed by a strong intellectual property portfolio, the DBSN™ device has the potential to provide truly personalized therapy by being able to adjust insulin production, as needed, for any individual. As previously reported, we are using our second NIH SBIR grant to focus on developing technology to treat the metabolic disorder, hypoglycemia. We believe we are on track to continue evaluating the DBSN™ device to address the large global diabetes market, reducing patient dependency on medication. As previously indicated, we continue to fund the development of DBSN™ through a non-dilutive funding strategy and potential strategic alliances.
About the Diabetes Bloc-Stim Neuromodulation™ Device
The Diabetes Bloc-Stim Neuromodulation™ (DBSN™) System is a novel therapeutic concept that is implanted in a minimally invasive manner and provides bioelectronic neuromodulation of the branches of the vagus nerve which are innervating organs that regulate plasma glucose. The DBSN™ System stimulates celiac vagal fibers in the pancreas to release insulin during stimulation, while blocking the hepatic vagal branch, innervating the liver, to decrease glucose release and decrease insulin resistance after ligation . The DBSN™ system uses a proprietary, reversible and adjustable electrical lockout considered key to the future of personalized medicine. The DBSN™ System is superior to both autonomic vagus nerve stimulation which has shown mixed results and vagus nerve ligation which has adverse effects.
About ReShape Lifesciences™
ReShape Lifesciences™ is America’s leading weight loss and metabolic health solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® program provides a long-term, minimally invasive treatment for obesity and is an alternative to more invasive surgical stapling procedures such as gastric bypass or sleeve gastrectomy. remodelcare™ is a virtual weight management program that supports lifestyle changes for all weight loss patients, led by board-certified health coaches to help them maintain weight over time. time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products for all consumers to help them achieve their health goals. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system uses a proprietary vagus nerve blocking and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® Balloon Technology is a non-surgical, swallowable, gas-filled intragastric balloon designed to provide sustained weight loss. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, mimicking the gastric volume reduction effect of conventional weight loss surgery. It helps to enable rapid weight loss in obese people without permanently altering the patient’s anatomy. For more information, please visit www.reshapelifesciences.com.
Safe Harbor Forward-Looking Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors. These forward-looking statements can generally be identified by the use of words such as “expect”, “plan”, “anticipate”, “could”, “could”, “intend”, “will”, “continue”, “future”, other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about our expectation that the marketing campaign will continue to promote increased demand for Lap Band® procedures and, therefore, potentially a significant increase in revenue for ReShape. These and other risks and uncertainties are described in more detail in the company’s filings with the Securities and Exchange Commission, including factors identified as “Risk Factors” in our most recent Annual Report on Form 10. -K and subsequent quarterly reports on Form 10-Q. . We provide this information as of the date of this press release and undertake no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise, except as required by law. .
ReShape Lifesciences Investor Contact:
Contact with Investor Relations:
Rx Communications Group